Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers

Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Related Keywords

Australia ,Japan ,Tokyo ,United States ,Northbrook ,Queensland ,United Kingdom ,America ,Japanese ,American ,Kenji Yasukawa ,Ahsan Arozullah ,Kohei Shitara ,National Cancer Center Hospital ,Astellas Pharma Inc ,End Results Program ,National Cancer Institute ,Head Of Development Therapeutic Areas ,Department Of Gastrointestinal Oncology ,American Cancer Society ,Primary Investigator ,Gastrointestinal Oncology ,National Cancer Center Hospital East ,Senior Vice President ,Development Therapeutic Areas ,South America ,Locally Advanced Unresectable Metastatic Gastric ,Gastroesophageal Junction ,Focus Area Approach ,Cancer Res ,Astellas Pharma ,End Results ,Cancer ,Food ,Medicine ,Spain ,Pharmaceuticals ,Clinical Medicine ,Her2 Neu ,Imab362 ,Monoclonal Antibodies ,Ramucirumab ,Stomach Cancer ,Targeted Therapy ,Trastuzumab Emtansine ,